03:31 PM EDT, 09/19/2024 (MT Newswires) -- Elanco Animal Health ( ELAN ) said Thursday that the US Food and Drug Administration approved Zenrelia to control itching linked with allergic dermatitis and atopic dermatitis in dogs at least 12 months old.

Zenrelia was at least as effective as market competitor Apoquel in a head-to-head study and 77% of dogs treated with Zenrelia achieved clinical remission of itch compared to 53% for Apoquel, according to the company.

Elanco said it is taking orders in the US and expects to ship the product in coming days.

Elanco shares were up almost 2% in recent trading.

Price: 14.91, Change: +0.25, Percent Change: +1.74